Vivoryon Therapeutics Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

1,60 EUR -0,01 EUR -0,87 %

09:08:18

FSE

1,60 EUR -0,03 EUR -1,60 %

09:56:47

GVIE

Vivoryon Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.48,27 Mio. EUR

Div. Rendite0,00%

WKNA2QJV6

ISINNL00150002Q7

SymbolVIVRF

Vivoryon Therapeutics Aktien News

Sortieren:Datum Meistgelesen

04.08.23GlobeNewswireVivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023

04.08.23GlobeNewswireVivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive Officer

16.07.23GlobeNewswireVivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease

21.06.23GlobeNewswireVivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General Meeting

15.06.23GlobeNewswireVivoryon Therapeutics N.V. Announces CEO Transition Plan

01.06.23GlobeNewswireVivoryon Therapeutics N.V. to Participate in Upcoming Conferences

26.05.23GlobeNewswireVivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million

25.05.23GlobeNewswireVivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering

16.05.23GlobeNewswireVivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress

09.05.23GlobeNewswireVivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023

09.05.23GlobeNewswireVivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023

01.05.23GlobeNewswireVivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting

24.04.23GlobeNewswireVivoryon Therapeutics N.V. to Participate in Upcoming Conferences

19.04.23GlobeNewswireVivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress

14.04.23GlobeNewswireVivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023

28.03.23GlobeNewswireVivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease

21.02.23GlobeNewswireVivoryon Therapeutics N.V. to Present at Upcoming Conferences

28.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)

23.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

22.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

Vivoryon Therapeutics News

Vivoryon Therapeutics News: auf dieser Seite finden Sie alle Vivoryon Therapeutics News und Nachrichten zur Vivoryon Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vivoryon Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vivoryon Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.